Cellipse

What Cellipse does

Cellipse is presented in firmographic inputs as a drug discovery company founded in 2013, headquartered in Grenoble, France, with 1–10 employees. Two co-founders are named: Fabrice Paublant (CEO & co-founder) and Renaud Prudent (COO & co-founder). Under that reading, the company would be a small, privately held French biotech with no disclosed funding rounds, customers, partnerships, patents, products, or revenue, and no explicit indication of active R&D, pipeline assets, or scientific publications in the input data.

The product, pricing, technology, revenue, and channel data in the same input package, however, describes Cellipse exclusively as a digital asset — specifically, an 8-letter premium .com domain name listed for sale on Atom's (formerly Squadhelp) premium domain marketplace. Under that reading, there is no operating company: no proprietary technology, no products or services beyond the domain itself, no headcount in the conventional sense, no office locations, no management team biographies, no regulatory filings, and no enterprise customers. The asset is priced at $2,888 for an outright purchase or $251/month for 12 months via a lease-to-own structure ($150 down payment), with global reach through Atom's marketplace and transaction processing via AtomPay. The domain is positioned to potential buyers in mobile apps, health/wellness devices, AI software, fitness, fashion, e-commerce, and electronics verticals.

These two readings are materially inconsistent and cannot be reconciled from the input alone. There is no corroborating evidence (website content, press coverage, scientific publications, regulatory records, customer logos, funding transactions) that links the Grenoble drug-discovery firmographics to the Atom-listed domain asset. For an investment audience, the entity as documented here lacks the verifiable operating substrate — revenue, customers, funding, IP, and an active website — to support either a biotech investment thesis or an active operating-company valuation. The most defensible characterization is that Cellipse.com is, at minimum, a parked premium domain asset of uncertain provenance, and any drug-discovery characterization in the firmographic layer is unsupported by the remainder of the data package.

Name

Cellipse

Website

https://cellipse.com

Company type

Private

Founded year

2013

Headcount range

1–10 employees

Short description

Cellipse is described in firmographic data as a drug discovery company founded in 2013 in Grenoble, France, with co-founders Fabrice Paublant and Renaud Prudent. Product and pricing evidence, however, describes Cellipse.com as a premium domain listed for sale on Atom's marketplace.

Ownership category

akta.pro rank

Product category

Drug Discovery

NAICS

Research and Development in Biotechnology (except Nanobiotechnology) (541714)

SIC

Pharmaceutical Preparations (2834)

akta.pro primary industry

In Vitro Model Systems & Organoid Platforms (iPSC/organoids, microphysiological systems) (HLAAAIAJ)

akta.pro secondary industry

Cell-Based & Potency Assays (Bioassays) (HLAGADAH)

Keywords

• Drug discovery services
• Preclinical research
• Biotechnology R&D
• Therapeutic development
• Pharmaceutical partnerships

Headquarters

HQ city

Grenoble

HQ country

France

HQ region

Europe

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Technology or R&D, Operations, Others

Pricing tiers

Distribution channels1 record

Core offering

Cellipse is classified in firmographic records as a drug discovery company headquartered in Grenoble, France, founded in 2013. No specific drug discovery services, platforms, pipelines, or deliverables are described in the available data. The company's online presence consists solely of a premium domain name (Cellipse.com) listed for sale on Atom's domain marketplace, with no evidence of an active operating website or product offering.

Product overview

Cellipse.com is a premium domain name (a single digital asset) being sold on Atom's domain marketplace. It is an 8-letter made-up word domain with .com extension. The domain is marketed as suitable for tech startups, mobile apps, health and wellness devices, and AI software companies. No additional products, modules, or services are associated with this offering beyond the domain name itself.

Differentiator

Problem solved

Functional benefit

Products and services

• Drug discovery services (per firmographic classification)

Segments1 record

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Recent moves1 record

Expansion highlights2 records

Broad incumbents

• Evotec: Global drug discovery and development CRO offering end-to-end services across multiple modalities. Comparable as the scaled incumbent in the drug discovery services space against which platform players like Cellipse must differentiate.
• Charles River Laboratories: Major preclinical CRO offering drug discovery and safety assessment services. Comparable as a broad incumbent that competes with smaller European discovery platforms for pharma outsourcing budgets.
• Eurofins Discovery: Division of Eurofins Scientific providing drug discovery and development services across Europe. Comparable as a large European-headquartered discovery services competitor.

Emerging players

• MIMETAS: Organ-on-chip and organoid-based drug discovery platform company. Comparable as a specialized European company providing in vitro model systems for drug discovery, similar to a cell-focused play.
• New Equilibrium Biosciences: AI-driven drug discovery platform focused on protein-protein interactions. Comparable as a small specialized discovery platform leveraging advanced technology to compete with larger CROs.
• Synaffix: European biotech providing antibody-drug conjugate (ADC) platform technology through partnerships. Comparable as a smaller European company monetizing proprietary technology through pharma partnerships.

Direct peers

• Domain Therapeutics: French drug discovery biotech based in Strasbourg focused on GPCR-based therapeutics. Comparable as a similarly-sized French drug discovery company operating in a specialized niche with potential pharma partnerships.
• OSE Immunotherapeutics: French clinical-stage biotech based in Nantes developing immunotherapies. Comparable as a French biotech company operating in the broader life sciences ecosystem with similar partnership dynamics.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat2 records

Key risks5 records

Key highlights4 records

Customer concentration

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cellipse